GnRH Pulsatile Patch – an infertility study

IRB #4832

The purpose of this study is to determine the safety and effectiveness of pulsatile GnRH delivered from a patch to stimulate ovulation in infertile women, compared to placebo (no medicine) and to a reference treatment with Clomid. Participants have a 4 out of 5 chance of receiving one active study drug and may be compensated up to $500 if all study visits are completed. If pregnancy is not achieved at the end of the 2 to 6 month trial, participants will receive a standard 5 day dose of Clomid.

Continuous Oral Contraceptive Study

IRB #2907

This is a four month opportunity using an FDA approved oral contraceptive to study the use of doxycyline in preventing breakthrough bleeding. Eligible participants will receive contraception and study drug at no cost. Participants will be compensated for time and travel.

Pelvic Floor Nerve Injury Following Childbirth

IRB #3196

This study looks at features of a woman’s anatomy, musculature and nerves before and after delivering a first child, as well as how those are associated with the lacerations (tears or cuts) and the symptoms of incontinence that happen as a result of childbirth.

Oral Contraception Study with an extended regimen

IRB #4703 (Dr. Jeffrey Jensen, M.D., M.P.H.)

The purpose of this study is to compare two different types of birth control drugs to find which is more effective at relieving hormone withdrawal-associated symptoms (specifically headache and pelvic pain): Ortho Tri-Cyclen Lo and SH T006581D/Qlaira. The investigational capsules consist of 26 hormonally active capsules followed by 2 inactive capsules. Qualifying participants in the approximately 1 year study will receive study related exams, blood tests, and study drug at no cost. Participants may be compensated up to $400 for time and travel.

Vaginal Anti-Progestin Ring

IRB #4464 (PI: Jeffrey Jensen, M.D., M.P.H.)

We are evaluating the safety, cycle control, and potential contraceptive effects of an investigational vaginal ring. Participants should have regular menstrual periods, be between the ages of 21 and 40, be in good general health, and not be considered at risk for pregnancy (sterile/have sterile partner, in same-sex partnership, or abstinent). Participants will be compensated up to $4200 for time and travel while they are in the study.

Pain and Immunity Study

IRB #4920 (PI: Beth Darnall, Ph.D.)

The purpose of this study is to learn how negative thoughts affect the immune systems of women with chronic pain. Women should be between the ages of 18 and 45, non-smoking, and have a diagnosis of muscle or bone pain for at least 13 months. Other eligibility criteria apply. The study involves 2 visits to OHSU. Participants may be compensated $160 for time and travel during the study.

BRIDGES Urge Urinary Incontinence Study

IRB #4123 (PI: Tom Gregory, M.D.)

The goal of this trial is to determine if diagnosing urge incontinence using a quick, 3 question assessment tool in a non-specialty setting results in effective treatment with Toviaz (fesoterodine) for urge urinary incontinence. Participants should be adult women with urge incontinence, interested in seeking treatment. 12 weeks of placebo controlled, blinded treatment followed by 9 months of open label treatment with an option for extended Urogynecology evaluation. Participants will be compensated up to $200 for time and travel while they are in the study.

TSH: Therapy for Imbalances in Thyroid Function during Pregnancy and Implications for Infant-Toddler Intellectual Development

IRB #2961 (PI: Jorge Tolosa. M.D.)

The purpose of this study is to see if it is important to treat women who have mild thyroid problems with thyroid medications during their pregnancy to improve the intellectual development of their babies. Participants should be less than 20 weeks pregnant and interested in being screened for thyroid problems. This screening is offered at no cost to participants. Other eligibility criteria apply.

Qualifying participants will receive placebo controlled, blinded treatment for thyroid problems for the length of their pregnancy. Additionally, their baby will be seen every year for five years to follow his/her development. Participants will be compensated up to $1,515 for their time.

SCAN: Prevention of Preterm Birth in First Time Mothers with a Short Cervix

IRB #3413 (PI: Jorge Tolosa, M.D.)

The purpose of this study is to see if weekly injections of a hormone called progesterone given in early stages of pregnancy will help prevent preterm birth in first-time moms who are found to have a short cervix. Participants should be currently 16 to 22 weeks pregnant and agree to a vaginal ultrasound to measure the length of their cervix. This ultrasound is offered at no cost to the participants. Other eligibility criteria apply.

If participants are found to have a short cervix, the study will include weekly injections of progesterone, as well as specialized care by our staff during pregnancy. Participants will be compensated $10 for each weekly injection.

Biomarkers in Maternal, Fetal, and Pediatric Health and Disease

IRB #0139 (PI: Leonardo Pereira, M.D.)

The purpose of this study is to understand the role of protein biomarkers in health and disease. We are looking for proteins produced by genes that are associated with different health and disease states of pregnancy or pediatrics. All pregnant women and newborns are eligible. There is no compensation for participants.

Recurrent Preterm Birth

IRB # 3954 (PI: Leonardo Pereira, M.D.)

The purpose of this study is to understand why some women are more likely to experience pre-term birth than others. Pregnant women with a history of only preterm birth(s) are eligible. There is no compensation for participants.

Infection in Amniotic Fluid (IAI)

IRB# 3777 (PI: Leonardo Pereira, M.D.)

The purpose of this study is to develop tests that may help doctors know if preterm labor is caused by an infection in amniotic fluid. Women in preterm labor at OHSU may be eligible for this study. There is no compensation for participants.

Coming soon!

Study opportunities in the areas of sterilization, continuous oral contraceptives, a new contraceptive ring, osteoporosis, low libido, the Human Papilloma Virus (genital wart virus), and hot flashes. Please call our confidential recruitment line at 503 494-3666 to learn more about these studies or to get on a wait list as a potential participant.